APLLTD:NSE-Alembic Pharmaceuticals Limited (INR)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSE

Last Closing Price

INR 931.10

Change

+16.50 (+1.80)%

Market Cap

INR 175.60B

Volume

0.42M

Average Target Price

INR 753.71 (-19.05%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and exports pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations. The company also provides branded and generic formulations in various therapeutic areas, such as cardio-diabetic, gynecology, acute, gastroenterology, ophthalmology, dermatology and cosmetology, urology, orthopedics, cancer, inflammation, autoimmune diseases, anti-infective, cold and cough, and metabolic disorders, as well as hospital care and animal health. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.

Employees : 11,130

Currency: INR

Country : India

Technical Indicators

Beta : 0.58

52 Week High : 983.15

52 Week Low : 434.80

200 Day Moving Average : 692.13

50 Day Moving Average : 882.73

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-08 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+3.25 (+0.68%)

 INR1,157.68B 28.61 14.91
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+63.20 (+1.65%)

 INR644.45B 33.40 20.54
DIVISLAB:NSE Divi's Laboratories Limited

-21.00 (-0.96%)

 INR574.34B 45.42 29.58
AUROPHARMA:NSE Aurobindo Pharma Limited

+25.70 (+3.31%)

 INR469.86B 17.76 10.83
LUPIN:NSE Lupin Limited

-5.10 (-0.59%)

 INR392.24B 49.28 18.18
CADILAHC:NSE Cadila Healthcare Limited

-2.15 (-0.59%)

 INR368.24B 30.10 16.73
ALKEM:NSE Alkem Laboratories Limited

+92.35 (+3.95%)

 INR290.27B 25.42 18.73
IPCALAB:NSE Ipca Laboratories Limited

-7.50 (-0.46%)

 INR206.60B 34.26 21.98
NATCOPHARM:NSE NATCO Pharma Limited

+3.25 (+0.48%)

 INR124.75B 26.00 16.56
AJANTPHARM:NSE Ajanta Pharma Limited

+21.60 (+1.54%)

 INR124.24B 26.27 15.68

ETFs Containing APLLTD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 69.08% 81% B- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.08% 81% B- 93% A
Trailing 12 Months  
Capital Gain 74.97% 80% B- 95% A
Dividend Return 1.03% 76% C 52% F
Total Return 76.00% 80% B- 95% A
Trailing 5 Years  
Capital Gain 25.02% 57% F 70% C-
Dividend Return 2.82% 61% D- 29% F
Total Return 27.84% 57% F 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 0.12% 45% F 40% F
Dividend Return 0.76% 75% C 51% F
Total Return 0.88% 45% F 39% F
Risk Return Profile  
Volatility (Standard Deviation) 19.60% 91% A- 92% A-
Risk Adjusted Return 4.48% 45% F 39% F
Market Capitalization 175.60B 86% B 91% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 20.40 61% D- 31% F
Price/Book Ratio 5.25 19% F 10% F
Price / Cash Flow Ratio 39.10 20% F 8% F
EV/EBITDA 15.76 31% F 21% F
Management Effectiveness  
Return on Equity 27.10% 96% A 94% A
Return on Invested Capital 20.69% 100% A+ 97% A+
Return on Assets 12.90% 96% A 95% A
Debt to Equity Ratio 27.55% 23% F 37% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.58 59% F 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.